Through our collaboration with Mary Tyler Moore Vision Initiative, we’re working alongside universities, foundations, and pharmaceutical and biotech companies to better detect, prevent, and treat vision loss from diabetes. Learn why preserving real-world vision must remain at the center of innovation 👇 #EyeHealth
Looking back, #ARVO2026 was full of exciting insights, fruitful conversations and great achievements. We engaged in more than four Think Tank meetings, held 16 collaboration discussions, and conducted 57 advisor consultations. We also supported two educational forums and hosted three on-booth events and two 4SIGHT NETWORK meetings. A key achievement was reinforcing the importance of the patient voice in drug development at #ARVO2026. My colleague Olivia Meyerhoffer met with Dr. Robert Levine to discuss some of the takeaways from the first Patient-Focused Drug Development meeting on diabetic retinal disease, organized by Mary Tyler Moore Vision Initiative. The meeting focused on the lived experiences of patients and caregivers to help shape what the future of care and treatment looks like. Their conversation highlighted a point we feel strongly about: preserving real-world vision (not just acuity) must remain at the center of innovation. People living with diabetic retinal disease experience meaningful changes in how they see and navigate their daily lives long before traditional clinical measures catch up. Reading, preparing a meal, driving a car. These are the moments where vision loss becomes real, and where our science must meet patients. That’s why advancing more meaningful functional endpoints matters so much. We need to measure what patients actually experience, not just what instruments can detect. Thank you to Olivia, Robert, and everyone involved in this effort for bringing the patient perspective to the forefront so powerfully ! #EyeHealth #DiabeticRetinopathy
Strong collaborations across research, academia, advocacy, and industry are essential to advancing innovation in eye health. It's encouraging to see continued focus on preserving real-world vision outcomes for individuals affected by diabetes-related vision loss. Thank you for supporting awareness, research, and patient-centered progress in this important area.